| Document |
Document Title |
|
WO/2022/243574A1 |
The present invention provides 3-(phthalazin-1-yl)benzenesulfonamide-based compounds of formula (I), Formula (I) and pharmaceutically acceptable salts thereof, which have been found to be advantageously potent and selective inhibitors of...
|
|
WO/2022/243683A1 |
A composition comprising at least one phyllosilicate mineral for use in the prevention and/or treatment of mycotoxic disease caused by sporidesmin and in particular for use in the prevention and or/treatment of pithomycotoxosis.
|
|
WO/2022/244852A1 |
The present invention addresses the problem of clarifying the relationship between the onset and progression of cancer and macrophages and providing a novel pharmaceutical composition for preventing or treating cancer. The present invent...
|
|
WO/2022/242692A1 |
Provided is use of an antibody-drug conjugate targeting Her2 in combination with an immune checkpoint inhibitor such as PD-1 antibody or PD-L1 antibody, in the preparation of a medicine for treating patients with urothelial cancer, espec...
|
|
WO/2022/244891A1 |
An antigen peptide which contains at least five continuous amino acid residues contained in the amino acid sequence represented by SEQ ID NO: 52, has an activity of inducing a cytotoxic T cell and/or a helper T cell, and can induce the c...
|
|
WO/2022/244846A1 |
The present invention provides a composition for regulating cell proliferation, said composition containing a regulator of D-amino acid content, or a composition that activates an mTOR-related pathway. The present invention also provides...
|
|
WO/2022/244915A1 |
The present invention relates to a composition comprising a euscaphic acid, and the use thereof for relieving fatigue and, more specifically, to a food composition, a health functional food composition, and/or a pharmaceutical compositio...
|
|
WO/2022/244692A1 |
The purpose of the present invention is to provide: a composition that contains 1'-acetoxychavicol acetate and that can enhance the anti-inflammatory action of 1'-acetoxychavicol acetate; and a method for preventing inflammation or for i...
|
|
WO/2022/246200A1 |
Methods of treating proteinuric glomerular diseases are provided, including methods comprising administering a compound having structure (I), or a pharmaceutically acceptable salt thereof, to a subject in need thereof. In some embodiment...
|
|
WO/2022/244876A1 |
The purpose of the present invention is to provide a new antitumor agent. Specifically, the present invention uses, as an antitumor agent, T-cells expressing a T-cell receptor including a peptide represented by SEQ ID NO: 1 and a peptide...
|
|
WO/2022/237878A1 |
Disclosed in the present invention are a crystal form of a compound, a composition containing the crystal form, a preparation method therefor and the use thereof. The crystal forms, i.e. crystal form I and crystal form II, of a compound ...
|
|
WO/2022/240035A1 |
A pharmaceutical composition according to the present invention is used in a specific therapeutic dosage regimen, and can be effectively used for the prevention or treatment of fibrosis.
|
|
WO/2022/240036A1 |
The present invention relates to a pharmaceutical composition that can be usefully used for the prevention or treatment of fibrosis. By using a first component and a second component together according to the present invention, the preve...
|
|
WO/2022/239715A1 |
[Problem] The purpose of the present invention is to provide formulation technology with which it is possible to suppress browning that occurs over time in a topical composition containing a non-steroidal anti-inflammatory, 0.015 wt% or ...
|
|
WO/2022/240116A1 |
The present invention provides a novel compound having an inhibitory activity against glucosylceramide synthase (GCS), i.e., compounds having a 2,3-dihydro-1H-indene, 1,2,3,4-tetrahydronaphthalene, or chromane moiety, or pharmaceutically...
|
|
WO/2022/238400A1 |
The present invention relates to a composition comprising: - at least one molecule covalently conjugated to a polylysine, and - at least one hydrophobic molecule which cannot be covalently conjugated to a polylysine, said molecule being ...
|
|
WO/2022/239068A1 |
The present invention relates to a novel cytokine storm inhibitor containing, as an active ingredient, a compound represented by general formula [1]: [in the formula, R1 R2, R3, R4, R5, and X are as defined in the description], or a phar...
|
|
WO/2022/239735A1 |
Provided is an industrially applicable apixaban purification method whereby high removability of analogous substances and a good re-crystallization yield are achieved. This apixaban purification method is characterized in that a base is ...
|
|
WO/2022/239870A1 |
A composition containing blood-derived growth factor more effective against wound healing and tissue regeneration, and a preparation method of said composition containing blood-derived growth factor are provided. One embodiment is a meth...
|
|
WO/2022/238403A1 |
The present invention relates to a composition comprising at least the following molecules: oleic acid, palmitic acid, lauric acid, linoleic acid, azelaic acid, farnesylcysteine, palmitoleic acid, cholesterol, thioctic acid, myristic aci...
|
|
WO/2022/237890A1 |
An azepine-type fused ring compound and a pharmaceutical use thereof. Specifically, involved are an azepine-type fused ring compound shown in general formula (I), a preparation method therefor, a pharmaceutical composition comprising sam...
|
|
WO/2022/239862A1 |
Provided are extracellular vesicles derived from cells that show reduced graft rejection and have a physiological activity. The composition according to the present invention contains extracellular vesicles of a regenerative cell popul...
|
|
WO/2022/239863A1 |
The present invention addresses the problem of providing an antisense oligomer capable of treating Werner's syndrome without direct mutated gene repair, or a pharmacologically acceptable salt of the antisense oligomer. The present inve...
|
|
WO/2022/234850A1 |
The present invention relates to: a composition which contains a compound represented by formula (1) or a salt thereof, or a solvate of the same; a liquid additive; and an optional oily component.
|
|
WO/2022/234852A1 |
Discovered were: a cyclic peptide compound that interacts with Ras; and a pharmaceutical composition comprising the cyclic peptide compound, a salt thereof, or a solvate thereof.
|
|
WO/2022/233625A2 |
Compositions and methods that use a combination of NARH and NR to produce intracellular NAD+/NADH. The compositions can be used in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. The compositions c...
|
|
WO/2022/234867A1 |
The present invention provides a compound represented by formula [I] having an MMP 7-inhibiting action or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/234855A1 |
The present invention provides a method for designing an oligonucleotide having a reduced central toxicity, the method being characterized by including a step for substituting a carbon atom at the 5' position of a sugar portion of at lea...
|
|
WO/2022/235050A1 |
The present invention relates to a composition for inhibiting tumor growth, containing an extract of Sanguisorba officinalis as an active ingredient. It has been identified that a Sanguisorba officinalis extract binds to PD-L1 on cancer ...
|
|
WO/2022/233460A1 |
The present invention belongs to the field of medicine, and more precisely to the field of medicine useful in the treatment of cardiac diseases with contributing mitochondrial dysfunction. The present invention relates to a composition a...
|
|
WO/2022/234853A1 |
The present inventors found a cyclic compound and an oligopeptide compound that selectively inhibit KRAS. The present inventors further found an oligopeptide compound and a non-natural amino acid that are useful for producing the cyclic ...
|
|
WO/2022/233872A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein n, m, A1, A2, A3, A4, A5, A6, L1, L2, R1, R2, R3, Y and Z are defined herein. Also provided herein are pharmaceutical compositions compris...
|
|
WO/2022/230987A1 |
A prophylactic or therapeutic agent for myopathy, containing a miR-33b inhibitor, preferably an antisense oligonucleotide against miR-33b, as an active ingredient.
|
|
WO/2022/230487A1 |
The purpose of the present invention is to provide: a composition for increasing red blood cells and/or hemoglobin; a composition for preventing or ameliorating anemia; a composition for improving endurance; an anti-fatigue composition; ...
|
|
WO/2022/232002A1 |
Aspects of the disclosure relates to composition and methods for treating Hermansky-Pudlak syndrome-associated pulmonary fibrosis in a subject. The disclosure is based, in part, on isolated nucleic acids and rAAVs encoding a Hermansky-Pu...
|
|
WO/2022/230494A1 |
The purpose of the present invention is to provide a composition for stimulating immune cell metabolism, a composition for immune activation, a method for stimulating immune cell metabolism, and a method for immune activation. The presen...
|
|
WO/2022/230912A1 |
The present invention addresses the problem of providing a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The present inventors hav...
|
|
WO/2022/230851A1 |
The present invention provides a novel prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis. Provided is a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis.
|
|
WO/2022/230489A1 |
The purpose of the present invention is to provide an anti-anxiety composition for humans and a method for preventing or improving anxiety symptoms. The present invention pertains to an anti-anxiety composition for humans that comprises ...
|
|
WO/2022/232356A1 |
Aspects disclosed herein include a method for treatment of a subject, the method comprising: topically administering a melanin formulation having an artificial melanin material (thereby administering artificial melanin material) to (or, ...
|
|
WO/2022/228223A1 |
An engineered mitochondria and a preparation method therefor. The engineered mitochondria binds to an outer membrane of an exogenous mitochondria by means of an exogenous cell membrane. The preparation method of the engineered mitochondr...
|
|
WO/2022/225045A1 |
The present invention addresses the problem of providing a therapeutic or prophylactic agent for cachexia accompanied by ghrelin resistance. The present invention provides a therapeutic or prophylactic agent for cachexia accompanied by g...
|
|
WO/2022/224172A1 |
The invention relates to the use of Aviptadil or a functional derivative or a precursor thereof alone or in combination with Alpha Lipoic Acid or a functional derivative or a precursor thereof as (a) therapeutic agent(s) for the prophyla...
|
|
WO/2022/223099A1 |
Suggested is a composition comprising or consisting of (a) Cannabidiol and optionally (b) Bisabolol for use as a medicament for prophylaxis and treatment of various dysfunctions of human skin triggered particularly by stress.
|
|
WO/2022/224820A1 |
The present invention provides: a compound represented by formula I, formula I', formula II, or formula II'; and a composition that is for regulating circadian rhythm and that contains said compound or an Agrocybe erebia culture.
|
|
WO/2022/225297A1 |
The present invention relates to a composition for the prevention, amelioration or treatment of cachexia, comprising a Lysimachiae Herba, Raphani Semen or Buddlejae Flos extract. The Lysimachiae Herba, Raphani Semen or Buddlejae Flos ext...
|
|
WO/2022/224372A1 |
The present application provides a novel means for treating ornithine transcarbamylase deficiency. More specifically, the present application provides a modified adeno-associated virus vector which expresses ornithine transcarbamylase so...
|
|
WO/2022/225203A1 |
The present invention relates to a liposome comprising phosphatidylserine and an RGD motif, and a composition for modulating macrophage activity, comprising phosphatidylserine and an RGD motif. A liposome, and a composition for modulatin...
|
|
WO/2022/226172A1 |
The present disclosure relates to compounds which increase y-oscillations in the brain. The disclosure further relates to methods of treating neurodegenerative diseases or disorders with the compounds disclosed herein.
|
|
WO/2022/225259A1 |
The present invention relates to an anticancer composition containing as an active ingredient a compound inducing cell senescence and cell death. The compound of the present invention can discriminate cancer cells and normal cells and in...
|
